|
|
|
News from 2019 European Society of Cardiology Congress, 31 August – 4 September, 2019
New approaches, new opportunities for PCSK9 inhibition
PCSK9 monoclonal antibody therapy is effective in patients with acute coronary syndrome (ACS) and stable atherosclerotic disease, as demonstrated by the landmark trials ODYSSEY OUTCOMES and FOURIER. But is it possible to consider initiating PCSK9 inhibition earlier, within 1 to 3 days of an ACS? The EVOPACS (EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes) Trial provided a rationale for evaluating this new therapeutic approach, showing efficacy and safety in an acute ACS setting.
Read the report »
|
Results of the first phase III trial, ORION-11, in patients at high cardiovascular risk were another highlight. Treatment with inclisiran was effective with a favourable safety profile. Moreover, the fact that inclisiran is administered every 6 months at the clinic ensures adherence.
Read the report »
Plus, more insights from ODYSSEY OUTCOMES – How to target PCSK9 inhibition to patients at highest risk and likely to obtain greatest benefit?
Read the report »
|
|
Don't miss our slide decks focusing on key results and expert analysis from FOURIER and ODYSSEY OUTCOMES
DOWNLOAD THEM NOW »
|
|
|
|
|
|
|
|
|
For the latest updates, PCSK9 news and analysis. |
|
Hot topics, news and conference reports. |
|
For videos, interviews and webcasts from leading experts. |
|
|
|
|
|
|
Educational Partners
and Supporters |
 |
|
 |
|
 |
|
|
|
| Copyright PCSK9 Forum 2019.
Please click here to unsubscribe from future mailings. |
|
|
